ABVC BioPharma, Inc. Files Restated Quarterly Report: Key Highlights for Investors

Overview and Purpose of the Report

ABVC BioPharma, Inc. has filed Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the period ended September 30, 2025. This amended filing restates certain financial information, management’s discussion and analysis, and related footnote disclosures from the previously issued unaudited quarterly financial statements. The restatement was prompted by management’s conclusion, on February 25, 2026, that the previously issued statements should no longer be relied upon due to material adjustments required in the value of a land acquisition.

Key Points Investors Should Know

• Restatement of Financials Due to Land Acquisition Valuation: The company concluded that the value of land acquired should be \$4,656,461, an increase of \$798,486 from the amount previously recognized. This adjustment is significant as it impacts the company’s asset base and related disclosures.
• Previous Financial Statements Superseded: All previously issued or reported quarterly financial statements, as well as any related earnings releases and investor communications, should no longer be relied upon. They are superseded by the information in this Form 10-Q/A.
• Reference to Note 2, Note 5, and Note 10: Investors are encouraged to review these notes for more details on the restatement and its impact.
• Nature of the Amendment: Other than the items described above, the amendment does not update or change any other item or disclosure from the original filing and does not reflect any events subsequent to the original filing date.

Financial Position and Performance

• Shareholder Equity and Share Count: As of September 30, 2025 (Restated), the company had 12,711,345 common shares outstanding and reported total equity including non-controlling interest at \$12,712. The company also had \$636,500 of ‘Stock to be issued’ and \$31,040 in the same line as of prior period restatement.
• Net Loss: The company reported a net loss attributable to shareholders of \$4,171,304 for the nine months ended September 30, 2025 (Restated). The basic and diluted net loss per share was (\$0.09) for the three months ended September 30, 2025, and (\$0.37) for the nine months ended September 30, 2025.
• Restated Results for Prior Periods: The company also restated its 2024 results for comparison, highlighting a net loss per share of (\$0.03) for the three months and (\$0.37) for the nine months ended September 30, 2024.

Price-Sensitive and Shareholder-Relevant Information

• The restatement of the asset value and associated increase in recognized cost of land may affect ABVC’s balance sheet strength and could be considered price sensitive, as it signals changes in asset values and management’s assessment of previously reported financials.
• Investors should note the company’s caution that previously published numbers should not be relied upon, which may impact market confidence in the company’s prior disclosures and has the potential to move the share price.
• The company’s ongoing losses and relatively low shareholder equity, compared to accumulated deficit, may raise concerns about future capital needs.
• The amendment also contains a robust “Cautionary Note on Forward Looking Statements” highlighting a range of risks, including the impact of COVID-19, competition, market volatility, and regulatory issues, particularly related to “penny stock” status.

Corporate Structure and Compliance

ABVC BioPharma, Inc. is categorized as a non-accelerated filer, smaller reporting company, and is not an emerging growth company. The company is current in its SEC filings and has submitted all required interactive data files electronically.

Conclusion

Investors should closely review this amendment and the referenced notes for a full understanding of the restatement’s impact on ABVC BioPharma, Inc.’s financial condition and results. The restatement of asset values and withdrawal of reliance on previous financials are material events that may affect market perception and share price volatility in the near term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the official filings and consult with a qualified financial advisor before making any investment decisions. The information presented may be subject to further updates, and past performance is no guarantee of future results.

View ABVC BIOPHARMA, INC. Historical chart here